Neumora Therapeutics Inc (NASDAQ:NMRA) has a beta value of 2.04 and has seen 1.18 million shares traded in the recent trading session. The company, currently valued at $337.66M, closed the recent trade at $2.09 per share which meant it lost -$0.03 on the day or -1.42% during that session. The NMRA stock price is -904.78% off its 52-week high price of $21.00 and 12.44% above the 52-week low of $1.83. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.66 million shares traded. The 3-month trading volume is 2.91 million shares.
The consensus among analysts is that Neumora Therapeutics Inc (NMRA) is Buy stock at the moment, with a recommendation rating of 1.44. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.37.
Neumora Therapeutics Inc (NASDAQ:NMRA) trade information
Sporting -1.42% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the NMRA stock price touched $2.09 or saw a rise of 4.13%. Year-to-date, Neumora Therapeutics Inc shares have moved -80.28%, while the 5-day performance has seen it change 1.95%. Over the past 30 days, the shares of Neumora Therapeutics Inc (NASDAQ:NMRA) have changed -81.21%. Short interest in the company has seen 12.99 million shares shorted with days to cover at 13.99.
Wall Street analysts have a consensus price target for the stock at $4, which means that the shares’ value could jump 47.75% from the levels at last check today. The projected low price target is $4.0 while the price target rests at a high of $4.0. In that case, then, we find that the latest price level in today’s session is -91.39% off the targeted high while a plunge would see the stock gain -91.39% from the levels at last check today.
Neumora Therapeutics Inc (NMRA) estimates and forecasts
Figures show that Neumora Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -83.16% over the past 6 months, with this year growth rate of 55.65%, compared to 16.40% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
Earnings growth for 2025 is a modest 55.97% while over the next 5 years, the company’s earnings are expected to increase by 25.54%.
NMRA Dividends
Neumora Therapeutics Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Neumora Therapeutics Inc (NASDAQ:NMRA)’s Major holders
Insiders own 27.47% of the company shares, while shares held by institutions stand at 66.36% with a share float percentage of 91.50%. Investors are also buoyed by the number of investors in a company, with Neumora Therapeutics Inc having a total of 154.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of Sep 30, 2024 , the former fund manager holds about 1.48% shares in the company for having 2.39 shares of worth $4.98 million while later fund manager owns 2.16 shares of worth $4.5 million as of Oct 31, 2024 , which makes it owner of about 1.34% of company’s outstanding stock.
